Overview

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Status:
Recruiting

Trial end date:
2026-07-31

Target enrollment:

Participant gender:

Summary

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

Phase:

Phase 2

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Cisplatin
Durvalumab
Tremelimumab